PillWork Strengthens Global Ties Ahead of 2023 Launch with Strategic Partnerships

SEOUL, South Korea, Nov. 12, 2023 /PRNewswire/ — PillWork, emerging as a pioneer in holistic wellness, is meticulously preparing for its anticipated launch at the end of 2023. As part of this build-up, PillWork has gained a place in the AWS Global Collaboration Program, ensuring top-tier app functionality. Furthermore, a collaboration with Vertical, Helsinki’s prestigious… Continue reading PillWork Strengthens Global Ties Ahead of 2023 Launch with Strategic Partnerships

Guardant Health launches Shield blood-based screening test for colorectal cancer in South Korea

SINGAPORE, Nov. 12, 2023 /PRNewswire/ — Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that it has launched its blood-based colorectal cancer screening test, ShieldTM, in collaboration with Samsung Medical Center in South Korea. Colorectal cancer (CRC) is one of the most commonly diagnosed cancers and the third-leading cause of cancer-related deaths… Continue reading Guardant Health launches Shield blood-based screening test for colorectal cancer in South Korea

First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591

MELBOURNE, Australia, Nov. 12, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in the Company’s Phase III ProstACT GLOBAL study of its investigational prostate-specific membrane antigen (PSMA) targeting radio-antibody drug conjugate (rADC) therapy, TLX591 (177Lu-rosopatamab tetraxetan). TLX591 is a rADC composed of a high-specificity… Continue reading First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591

First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591

MELBOURNE, Australia, Nov. 12, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in the Company’s Phase III ProstACT GLOBAL study of its investigational prostate-specific membrane antigen (PSMA) targeting radio-antibody drug conjugate (rADC) therapy, TLX591 (177Lu-rosopatamab tetraxetan). TLX591 is a rADC composed of a high-specificity… Continue reading First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591

ROSEN, A LONGSTANDING LAW FIRM, Encourages Nikola Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – NKLA

NEW YORK, Nov. 12, 2023 /PRNewswire/ — WHY:  Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nikola Corporation (NASDAQ: NKLA) between February 24, 2022 and September 7, 2023, both dates inclusive (the “Class Period”), of the important December 12, 2023 lead plaintiff deadline. SO WHAT: If you purchased Nikola securities… Continue reading ROSEN, A LONGSTANDING LAW FIRM, Encourages Nikola Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – NKLA

Xinhua Silk Road: 2023 China (Zhejiang) Forum on China-Africa Economic and Trade Relations kicks off E. China’s Jinhua

BEIJING, Nov. 12, 2023 /PRNewswire/ — The opening ceremony of the 2023 China (Zhejiang) Forum on China-Africa Economic and Trade Relations and China-Africa Cultural Cooperation and Exchange Month kicked off on Wednesday in Jinhua City, east China’s Zhejiang Province. The forum, co-sponsored by the Chinese People’s Association for Friendship with Foreign Countries, the China Council… Continue reading Xinhua Silk Road: 2023 China (Zhejiang) Forum on China-Africa Economic and Trade Relations kicks off E. China’s Jinhua

Everett Stern issues a critical letter and report to the President of The United States

ST. AUGUSTINE, Fla., Nov. 12, 2023 /PRNewswire/ — Whistleblower and former US Senate candidate Everett Stern has issued a critical letter to the President of the United States concerning the current state of the Israel Hamas war. The letter and report can be read here https://open.substack.com/pub/everettstern/p/letter-to-president-biden?r=1dhx1e&utm_campaign=post&utm_medium=web. Continue Reading Everett Stern in Israel The US has… Continue reading Everett Stern issues a critical letter and report to the President of The United States

Starch Derivatives Market worth $68.4 billion by 2028 – Exclusive Report by MarketsandMarkets™

CHICAGO, Nov. 12, 2023 /PRNewswire/ — The Starch Derivatives Market is projected to reach USD 68.4 billion by 2028 from USD 57.9 billion by 2023, at a CAGR of 3.4% from 2023 to 2028 according to a report published by MarketsandMarkets™. The starch derivatives market is experiencing growth due to increasing demand for processed foods, pharmaceuticals,… Continue reading Starch Derivatives Market worth $68.4 billion by 2028 – Exclusive Report by MarketsandMarkets™

Xinhua Silk Road: Lotus festival in E. China’s Nanchang county yields fruitful economic and trade results

BEIJING, Nov. 12, 2023 /PRNewswire/ — The 7th Lotus Economic, Trade and Cultural Festival has recently concluded in Nanchang County (Xiaolan Economic and Technological Development Zone), east China’s Jiangxi Province. Spanning three months, the comprehensive event included over 40 activities, ranging from cultural activities, tourism experiences to business events, such as signing ceremonies, business matchmaking and… Continue reading Xinhua Silk Road: Lotus festival in E. China’s Nanchang county yields fruitful economic and trade results

ROSEN, A LONGSTANDING LAW FIRM, Encourages DLocal Limited Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – DLO

NEW YORK, Nov. 12, 2023 /PRNewswire/ — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DLocal Limited (NASDAQ: DLO) between May 2, 2022 and May 25, 2023, both dates inclusive (the “Class Period”), of the important December 5, 2023 lead plaintiff deadline. SO WHAT: If you purchased DLocal securities… Continue reading ROSEN, A LONGSTANDING LAW FIRM, Encourages DLocal Limited Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – DLO